The small molecule drug arimoclomol (Miplyffa) has got the green light from the U.S. Food and Drug Administration (FDA) for ...
The US biotech’s neurological drug candidate showed a reduction in disease progression of at least 50% and the company will ...
The Hong Kong headquartered company says its idiopathic pulmonary fibrosis drug performed well in a phase 2a trial and met ...
The series A financing will enable Nura Bio to advance its lead drug candidate into the next stage of clinical trials, ...
The series A financing will enable Nura Bio to advance its lead drug candidate into the next stage of clinical trials, shortly after successfully completing a first phase 1 clinical trial.
She brings her global experience across multiple therapeutic areas to her current role leading operations at YPrime. In this ...
The German big pharma will submit a new drug application to the US FDA after success at phase 3 for nerandomilast.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback